Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
Hormones and Cancer · 2014-12 · 5 (6) · 405-413
DOI: 10.1007/s12672-014-0196-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormones and Cancer, 2014-12. Verfasst von Anieta M Sieuwerts und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Dr. Molewaterplein 50, 3015 GE, Rotterdam, Netherlands. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NCATS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Recent observations connected DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. We addressed whether APOBEC3B is associated with breast cancer clinical outcomes. APOBEC3B messenger RNA (mRNA) levels were related in 1,491 primary breast cancers to disease-free (DFS), metastasis-free (MFS), and overall survival (OS). For independent validation, APOBEC3B mRNA expression was associated with patient outcome data in five additional cohorts (over 3,500 breast cancer cases). In univariate Cox regression analysis, increasing APOBEC3B expression as a continuous variable was associated with worse DFS, MFS, and OS (hazard ratio [HR] = 1.20, 1.21, and 1.24, respectively; all P < .001). Also, in untreated ER-positive (ER+), but not in ER-, lymph-node-negative patients, high APOBEC3B levels were associated with a poor DFS (continuous variable: HR = 1.29, P = .001; dichotomized at the median level, HR = 1.66, P = .0002). This implies that APOBEC3B is a marker of pure prognosis in ER + disease. These findings were confirmed in the analyses of five independent patient sets. In these analyses, APOBEC3B expression dichotomized at the median level was associated with adverse outcomes (METABRIC discovery and validation, 788 and 706 ER + cases, disease-specific survival (DSS), HR = 1.77 and HR = 1.77, respectively, both P < .001; Affymetrix dataset, 754 ER + cases, DFS, HR = 1.57, P = 2.46E-04; NKI295, 181 ER + cases, DFS, HR = 1.72, P = .054; and BIG 1-98, 1,219 ER + cases, breast-cancer-free interval (BCFI), HR = 1.42, P = 0.0079). APOBEC3B is a marker of pure prognosis and poor outcomes for ER + breast cancer, which strongly suggests that genetic aberrations induced by APOBEC3B contribute to breast cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Dr. Molewaterplein 50, 3015 GE, Rotterdam, Netherlands.
Förderung
- NCRR NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Sieuwerts, A. M., Willis, S., Burns, M. B., Look, M. P., Meijer-Van Gelder, M. E., Schlicker, A., Heideman, M. R., Jacobs, H., Wessels, L., Leyland-Jones, B., Gray, K. P., Foekens, J. A., Harris, R. S., & Martens, J. W. (2014). Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer. https://doi.org/10.1007/s12672-014-0196-8
Vancouver
Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer. 2014. doi:10.1007/s12672-014-0196-8
BibTeX
@article{Sieuwerts2014,
author = {Sieuwerts, Anieta M and Willis, Scooter and Burns, Michael B and Look, Maxime P and Meijer-Van Gelder, Marion E and Schlicker, Andreas and Heideman, Marinus R and Jacobs, Heinz and Wessels, Lodewyk and Leyland-Jones, Brian and Gray, Kathryn P and Foekens, John A and Harris, Reuben S and Martens, John W M},
title = {Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers},
journal = {Hormones and Cancer},
year = {2014},
doi = {10.1007/s12672-014-0196-8}
}
EUVIMED